Kommentar zu „Dapagliflozin auch bei erhaltener Ejektionsfraktion effektiv“

• Literatur

• 1 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381 (21) 1995-2008
• 2 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383 (15) 1413-1424
• 3 Berg DD, Jhund PS, Docherty KF. et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 2021; 6 (05) 499-507
• 4 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385 (16) 1451-1461
• 5 Schulze PC, Bogoviku J, Westphal J. et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation 2022; 146 (04) 289-298